Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_assertion description "[Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_assertion evidence source_evidence_literature NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_assertion SIO_000772 25192874 NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_assertion wasDerivedFrom befree-2016 NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_assertion wasGeneratedBy ECO_0000203 NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.
- befree-2016 importedOn "2016-02-19" NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.